Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Lineberry

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Research Communications|November 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid TumorsBenjamin T Cooper, Wade T Iams, David B Page, et al.
Cancer Immunology Research|June 9, 2022
Activation of Tumor-Cell STING Primes NK-Cell TherapyErik H Knelson, Elena V Ivanova, Mubin Tarannum, et al.
Cancer Cell|March 6, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerMarco Campisi, Tatsuya Osaki, Ian Dryg, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Research Communications|November 26, 2025
Phase 1b Study of Dazostinag plus Pembrolizumab after Hypofractionated Radiotherapy in Patients with Select Advanced Solid TumorsBenjamin T Cooper, Wade T Iams, David B Page, et al.
Cancer Immunology Research|June 9, 2022
Activation of Tumor-Cell STING Primes NK-Cell TherapyErik H Knelson, Elena V Ivanova, Mubin Tarannum, et al.
Cancer Cell|March 6, 2026
Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancerMarco Campisi, Tatsuya Osaki, Ian Dryg, et al.
Pageof 2